Barings’s iShares Biotechnology ETF IBB Stock Holding History

Barings’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-26,256	Closed	-$2.57M	–	913
2017 Q1	$2.57M	Buy	26,256 +23,256	+775%	+$2.23M	0.03%	524
2016 Q4	$265K	Hold	3,000	–	–	0.01%	797
2016 Q3	$289K	Buy	+3,000	New	+$285K	0.01%	693

Other funds holding IBB

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Barings's IBB Position: Q2 2017 in Review

Barings sold out of iShares Biotechnology ETF (IBB) in Q2 2017, closing a stake of 26,256 shares — an estimated $2.57M sold.

Barings first reported a position in IBB in Q3 2016 and held it in 3 quarters. The position peaked at $2.57M in Q1 2017. 561 funds tracked by Wall St. Rank hold IBB as of Q2 2017.

Barings reported no remaining iShares Biotechnology ETF position as of Q2 2017 after selling out during the quarter.
Barings sold 26,256 iShares Biotechnology ETF shares in Q2 2017, an estimated $2.57M.
Barings first reported a position in iShares Biotechnology ETF in Q3 2016 and held it in 3 quarters.
Barings's iShares Biotechnology ETF position peaked at $2.57M in Q1 2017.
561 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2017.

Based on Barings's 13F filing for Q2 2017, filed 14 Aug 2017.